A Randomized Multicenter Study Comparing 0.1%, 0.15%, and 0.3% Sodium Hyaluronate with 0.05% Cyclosporine in the Treatment of Dry Eye
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Yuli | - |
dc.contributor.author | Song, Jong Suk | - |
dc.contributor.author | Choi, Chul Young | - |
dc.contributor.author | Yoon, Kyung Chul | - |
dc.contributor.author | Lee, Hyung Keun | - |
dc.contributor.author | Kim, Hyun Seung | - |
dc.date.accessioned | 2021-09-03T09:06:15Z | - |
dc.date.available | 2021-09-03T09:06:15Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2017-03 | - |
dc.identifier.issn | 1080-7683 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/84323 | - |
dc.description.abstract | Purpose: To investigate the efficacy of 0.1%, 0.15%, and 0.3% sodium hyaluronate (SH) artificial tears compared with 0.05% cyclosporine (CS) ophthalmic solution for the treatment of dry eye. Methods: One hundred seventy-six patients were recruited and randomized to receive of 0.1%, 0.15%, and 0.3% SH and 0.05% CS. There was a primary end point which is the changes in the fluorescein corneal staining (FCS) score to determine noninferiority of 0.1%, 0.15%, and 0.3% SH. Secondary objective end points were lissamine green conjunctival staining (LGCS) scores, Schirmer test, and tear film break-up time (TBUT). Secondary subjective end point was ocular surface disease index (OSDI) score. These were evaluated before treatment and 6 and 12 weeks after start of treatment. Results: In the primary analysis, the mean change from baseline in FCS scores verified noninferiority of 0.1% and 0.15% SH to 0.05% CS and also indicated significant improvement of all groups (P < 0.05). Values for TBUT, LGCS scores, and OSDI scores showed significant improvements in all groups (P < 0.05), although no significant intergroup difference was shown. However, Schirmer test scores in the 0.15% SH group showed a significant tendency for better improvement at week 12 compared with the other groups (P < 0.05). No serious adverse events were observed. Conclusions: Administration of 0.1%, 0.15%, and 0.3% SH was effective in improving both the objective signs and subjective symptoms of dry eye. Those findings, in addition to the well-tolerated profile of 0.1%, 0.15%, and 0.3% SH, show that it is effective therapeutic method for dry eye. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | MARY ANN LIEBERT, INC | - |
dc.subject | OCULAR SURFACE | - |
dc.subject | ARTIFICIAL TEARS | - |
dc.subject | OPHTHALMIC EMULSION | - |
dc.subject | OPTICAL-QUALITY | - |
dc.subject | EYEDROPS | - |
dc.subject | DISEASE | - |
dc.subject | PERFORMANCE | - |
dc.subject | EFFICACY | - |
dc.subject | CELLS | - |
dc.subject | MODEL | - |
dc.title | A Randomized Multicenter Study Comparing 0.1%, 0.15%, and 0.3% Sodium Hyaluronate with 0.05% Cyclosporine in the Treatment of Dry Eye | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Song, Jong Suk | - |
dc.identifier.doi | 10.1089/jop.2016.0086 | - |
dc.identifier.scopusid | 2-s2.0-85014005673 | - |
dc.identifier.wosid | 000394591400002 | - |
dc.identifier.bibliographicCitation | JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, v.33, no.2, pp.66 - 72 | - |
dc.relation.isPartOf | JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS | - |
dc.citation.title | JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS | - |
dc.citation.volume | 33 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 66 | - |
dc.citation.endPage | 72 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Ophthalmology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Ophthalmology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | OCULAR SURFACE | - |
dc.subject.keywordPlus | ARTIFICIAL TEARS | - |
dc.subject.keywordPlus | OPHTHALMIC EMULSION | - |
dc.subject.keywordPlus | OPTICAL-QUALITY | - |
dc.subject.keywordPlus | EYEDROPS | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | PERFORMANCE | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | CELLS | - |
dc.subject.keywordPlus | MODEL | - |
dc.subject.keywordAuthor | dry eye syndrome | - |
dc.subject.keywordAuthor | 0.1% sodium hyaluronate | - |
dc.subject.keywordAuthor | 0.15% sodium hyaluronate | - |
dc.subject.keywordAuthor | 0.3% sodium hyaluronate | - |
dc.subject.keywordAuthor | 0.05% cyclosporine | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.